GREENLAND MINES LTD (GRML)
NASDAQHealth CareOther Precious MetalsSnapshot 2026-10-30
$4.58-10.89%
Close 2026-10-30 · 1-day change
NASDAQHealth CareOther Precious MetalsSnapshot 2026-10-30
Research Workspace
Put GRML beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisThis stock is highly volatile — it swings about 6% on a typical day and fell roughly 91% in its worst 12-month stretch.
View RiskGRML rests on developing rare earth projects as a Western supply alternative. The desk has no earnings release or revenue history to confirm growth. Its president described the Skaergaard and Sarfartoq projects and capital access. The company is unprofitable, with weak recent performance and unsteady management. No valuation multiple or peer comparison is available in the desk. Management is behind on a stated commitment, the cited thesis risk. No next-quarter miss probability is available in the desk. Peer multiples do not provide a valuation read; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. GRML is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 1 analyst currently covering GRML (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare GRML with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GRML Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-11-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Diversified Metals & Mining — fair value, gap to price, and forward P/E.
Compare the value case
Put GRML next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance multi-asset platform in rare earths and biotech sectors
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
EU designation supports rare earths platform advancement.
Advances: Advance multi-asset platform in rare earths and biotech sectors
Advances multi-asset platform in rare earths sector.
Threatens: Capital raising through public offerings and equity sales
Funding and dilution concerns may hinder capital raising efforts.
Advances: Advance multi-asset platform in rare earths and biotech sectors
Management's outline supports advancing multi-asset platform objectives.
Advances: Capital raising through public offerings and equity sales
Capital raising supports growth and strategic objectives.
Advances: Capital raising through public offerings and equity sales
Capital raising supports growth initiatives and M&A objectives.
Advances: Capital raising through public offerings and equity sales
Capital raise supports growth and financial stability.
Advances: Advance multi-asset platform in rare earths and biotech sectors
Strengthens position in rare earths sector amid geopolitical support.
